Praxis Precision Medicines, Inc. (PRAX)
NASDAQ: PRAX · Real-Time Price · USD
73.68
+0.93 (1.28%)
Nov 20, 2024, 4:00 PM EST - Market closed
PRAX Employees
Praxis Precision Medicines had 82 employees as of December 31, 2023. The number of employees decreased by 27 or -24.77% compared to the previous year.
Employees
82
Change (1Y)
-27
Growth (1Y)
-24.77%
Revenue / Employee
$19,573
Profits / Employee
-$1,841,683
Market Cap
1.37B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82 | -27 | -24.77% |
Dec 31, 2022 | 109 | -30 | -21.58% |
Dec 31, 2021 | 139 | 72 | 107.46% |
Dec 31, 2020 | 67 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Myriad Genetics | 2,700 |
Indivior | 1,164 |
MiMedx Group | 895 |
Alphatec Holdings | 839 |
Arcus Biosciences | 577 |
Syndax Pharmaceuticals | 184 |
Day One Biopharmaceuticals | 155 |
Cassava Sciences | 29 |
PRAX News
- 14 days ago - Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences - GlobeNewsWire
- 14 days ago - Praxis Precision Medicines, Inc. (PRAX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 20 days ago - Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024 - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine - GlobeNewsWire
- 2 months ago - Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024 - GlobeNewsWire
- 3 months ago - These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results - Benzinga